ARM’s virtual 2022 Cell & Gene State of the Industry Briefing attracted over 700+ key stakeholders in the field. This event included ARM’s annual yearly update on the sector’s progress followed by two panel sessions featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.
2022 Cell & Gene State of the Industry Briefing
Introduction & Industry Update
Janet Lambert, CEO, Alliance for Regenerative Medicine
Emile Nuwaysir, Ph.D., CEO, Ensoma; Chairman, Alliance for Regenerative Medicine (ARM); Chairman, BlueRock Therapeutics
2022: A Banner Year for Rare Genetic Disease Therapies?
Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer Inc. (Moderator)
Harold Bernstein, M.D., Ph.D., Chief Medical Officer and Senior Vice President, BioMarin
Jason Cole, Chief Business Officer, bluebird bio
Bobby Gaspar, M.D., Ph.D., CEO, Orchard Therapeutics
Suma Krishnan, Founder and Chief Operating Officer, Krystal Biotech
Next Generation Therapies to Fight Cancer
Robert Ang, CEO, Vor Biopharma (Moderator)
Osvaldo Flores, Ph.D., CEO, Century Therapeutics
Steven Kelly, President and CEO, Carisma Therapeutics
Alison Moore, Ph.D., Chief Technical Officer, Allogene Therapeutics
Over 700 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.